3,5-dihydro-1H-thieno[3,4-c]pyrrole | 63156-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡咯类
• 英文名称: 3,5-dihydro-1H-thieno[3,4-c]pyrrole
• 英文别名: 1,3-dihydrothieno[3,4-c]pyrrole
• CAS: 63156-10-5
• 化学式: C₆H₇NS
• mdl: MFCD18810581
• 分子量: 125.194
• InChiKey: PACRFWGPIBIQLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  41.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,5-dihydro-1H-thieno[3,4-c]pyrrole 、 六氟苯 在 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 3.17h， 以47%的产率得到N-pentafluorophenyl-1,3-dihydrothieno[3,4-c]pyrrole
  参考文献：
  名称：

  Oxidation Behavior of 1,3-Dihydrothieno[3,4-a]HPHAC

  摘要：

  通过六氟苯与 1,3-二氢噻吩并[3,4-c]吡咯和 3,4-二己基吡咯的连续 SNAr 反应，然后进行 Scholl 氧化，制备了 1,3-二氢噻吩并[3,4-a]-和 1,3,8,10-四氢二噻吩并[3,4-a;3′4′-m]-HPHACs。在室温下，用过量的碘氧化 1,3-二氢噻吩融合的 HPHAC，可定量得到相应的双(三碘)二元酸。通过除去反应过程中产生的碘化氢，在更高温度下用碘进一步脱氢氧化二ication 物，得到噻吩并[3,4-a]HPHAC 二ication 物。无法分离出噻吩并[3,4-a]HPHAC 的中性物质。

  DOI：

  10.1246/bcsj.20190022
• 作为产物：
  描述：

  3,4-吡咯二羧酸二乙酯 在 sodium sulfide 、 lithium aluminium tetrahydride 、 三溴化磷 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 51.17h， 生成 3,5-dihydro-1H-thieno[3,4-c]pyrrole
  参考文献：
  名称：

  Calix[4]tetrahydrothiophenopyrrole: A Ditopic Receptor Displaying a Split Personality for Ion Recognition

  摘要：

  A calix[4]pyrrole fused with 2,5-dihydrothiophene, possessing both a deep, pi-electron-rich pocket upon anion binding and chelating ligands on the periphery, was developed. The receptor selectively forms an ion-pair complex with CsF through H-bonding and a cation-pi interaction. In the process, it adopt a conformationally fixed cone conformation. The receptor displays exceptionally high affinity toward the Hg(II) ion and forms stable complexes while maintaining a rigid 1,3-alternate conformation. This metal ion-induced conformational locking is unprecedented in calix[4]pyrrole chemistry.

  DOI：

  10.1021/ol5026537

文献信息

• [EN] SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS DE DCN1 À PETITES MOLÉCULES ET PROCÉDÉS THÉRAPEUTIQUES LES UTILISANT
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2018183411A1

  公开（公告）日：2018-10-04

  Compounds of formula (I) as inhibitors of DCNl and compositions containing the same are disclosed. Methods of using the DCNl inhibitors in the treatment of diseases and conditions wherein inhibition of DCNl provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  公式（I）的化合物被披露为DCNl的抑制剂，以及含有这些化合物的组合物。还披露了在治疗疾病和病况中使用DCNl抑制剂的方法，其中DCNl的抑制提供益处，如氧化应激相关的疾病和病况、神经退行性疾病和病况、代谢紊乱以及肌肉神经退化。
• Covalent Small Molecule DCN1 Inhibitors and Therapeutic Methods Using the Same
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20180289677A1

  公开（公告）日：2018-10-11

  Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.

  揭示了DCN1的小分子共价抑制剂和含有这些抑制剂的组合物。还揭示了在治疗疾病和状况中使用DCN1共价抑制剂的方法，其中DCN1的抑制提供益处，如氧化应激相关的疾病和状况、神经退行性疾病和状况、代谢紊乱以及肌肉神经退化。
• Novel imidazolic compounds, method for preparing same and use thereif as medicines
  申请人：Vacher Bernard

  公开号：US20060041001A1

  公开（公告）日：2006-02-23

  The invention provides compounds having the formula (1): wherein R1 is hydrogen, fluoro or methoxyl, R1 being in position 2, 3, 4 or 5 of the aromatic carbocycle; R2 is hydrogen or methyl; R3 is hydrogen, methyl or ethyl; and their pharmaceutically acceptable acid addition salts, hydrates of their pharmaceutically acceptable acid addition salts as well as the isomers and the tautomers thereof.

  这项发明提供具有以下化学式（1）的化合物：其中R1是氢、氟或甲氧基，R1位于芳香碳环的2、3、4或5位置；R2是氢或甲基；R3是氢、甲基或乙基；以及它们的药用可接受酸盐、药用可接受酸盐的水合物，以及它们的异构体和互变异构体。
• Pyrrole derivative and process for producing the same
  申请人：Kato Masahiko

  公开号：US20050222241A1

  公开（公告）日：2005-10-06

  An object of the present invention is to provide novel pyrrole derivatives and processes for producing the derivatives, and to provide novel pyrrole derivatives (intermediates) which may be used as a starting material for the pyrrole derivatives and processes for producing the derivatives (intermediates). The pyrrole derivatives may be characterized by being represented by the formulae [1] and [2] wherein R 1 and R 2 each independently represents a hydrogen atom or a substituted or unsubstituted C 1-10 hydrocarbon group and Z represents an organic group; and the process for producing the compound represented by the formula [1] may be characterized by separating Z from the compound represented by the formula [2].

  本发明的目的是提供新的吡咯衍生物及其生产过程，并提供可用作吡咯衍生物和衍生物（中间体）起始物的新的吡咯衍生物（中间体）和生产衍生物（中间体）的过程。所述吡咯衍生物可由式[1]和[2]表示，其中R1和R2各自独立地表示氢原子或取代或未取代的C1-10烃基，Z表示有机基团；生产式[1]所表示的化合物的过程可通过从式[2]所表示的化合物中分离Z来特征化。
• PYRROLE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
  申请人：NIPPON SODA CO., LTD.

  公开号：EP1557419A1

  公开（公告）日：2005-07-27

  An object of the present invention is to provide novel pyrrole derivatives and processes for producing the derivatives, and to provide novel pyrrole derivatives (intermediates) which may be used as a starting material for the pyrrole derivatives and processes for producing the derivatives (intermediates). The pyrrole derivatives may be characterized by being represented by the formulae [1] and [2] wherein R1 and R2 each independently represents a hydrogen atom or a substituted or unsubstituted C1-10 hydrocarbon group and Z represents an organic group; and the process for producing the compound represented by the formula [1] may be characterized by separating Z from the compound represented by the formula [2].

  本发明的目的是提供新型吡咯衍生物及其制备方法，以及可作为吡咯衍生物和制备方法（中间体）的起始物的新型吡咯衍生物（中间体）。这些吡咯衍生物可以通过以下公式[1]和[2]表示，其中R1和R2各自独立地表示氢原子或取代或未取代的C1-10烃基，Z表示有机基团；制备由公式[1]表示的化合物的方法可以通过从公式[2]表示的化合物中分离Z来实现。